<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1137</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2019-18-1-16-24</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Vasculogenic mimicry in melanoma: molecular mechanisms and clinical significance</article-title><trans-title-group xml:lang="ru"><trans-title>Васкулогенная мимикрия при меланоме: молекулярные механизмы и клиническое значение</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rotin</surname><given-names>D. L.</given-names></name><name xml:lang="ru"><surname>Ротин</surname><given-names>Д. Л.</given-names></name></name-alternatives><address><country country="IL">Israel</country></address><bio xml:lang="en"><p>2 Derech Sheba, Ramat Gan 52621, Israel</p></bio><bio xml:lang="ru"><p>Израиль, 52621 Рамат-Ган, Дорога Шиба, 2;</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Titov</surname><given-names>K. S.</given-names></name><name xml:lang="ru"><surname>Титов</surname><given-names>К. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>86 Shosse Entuziastov, Moscow 111123</p></bio><bio xml:lang="ru"><p>111123 Москва, ш. Энтузиастов, 86</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9534-2729</contrib-id><name-alternatives><name xml:lang="en"><surname>Kazakov</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Казаков</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashyrskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское ш., 24</p></bio><email>hordavii@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sheba State Hospital of Israel (Tel HaShomer)</institution></aff><aff><institution xml:lang="ru">Государственная Израильская больница «Шиба» (Тель ха-Шомер)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">A.S. Loginov Moscow Clinical and Scientific Center, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Московский клинический научный центр им. А.С. Логинова» Департамента здравоохранения г. Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-04-19" publication-format="electronic"><day>19</day><month>04</month><year>2019</year></pub-date><volume>18</volume><issue>1</issue><issue-title xml:lang="ru"/><fpage>16</fpage><lpage>24</lpage><history><date date-type="received" iso-8601-date="2019-04-19"><day>19</day><month>04</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-04-19"><day>19</day><month>04</month><year>2019</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1137">https://bioterapevt.abvpress.ru/jour/article/view/1137</self-uri><abstract xml:lang="en"><p>The concept of vasculogenic mimicry (VM) was introduced to describe the unique ability of highly aggressive tumor cells to form capillary-like structures and matrix-rich patterned network in three-dimensional culture that mimic embryonic vasculogenic network. VM has been reported in several aggressive tumors including ovaries, breast, liver, lung cancer, sarcoma, glioblastoma. It is worth to note, that VM in melanocyte-originated tumors is the most studied. Although much attention has been focused on factors that stimulate or suppress vascular channel formation by tumor cells, the molecular mechanisms underlying this phenomenon remain enigmatic. This review will focus on molecular determinants and key signaling pathways involved in tumor VM. The exploration of drugs targeted at molecular signaling pathways in VM is a field of challenges and hopes. The research on VM will increase our knowledge of the molecular events causing aggressive tumor cells to gain plasticity resulting in their ability to mimic vasculature. To date, little functional data exist that show how tumor cell-lined channels contribute to the overall survival of the tumor. However, even among researches who have questioned the concept of VM as a crucial circulatory system, there is generally a consensus that the prognostic significance of PAS-positive patterns is valid.</p></abstract><trans-abstract xml:lang="ru"><p>Концепция васкулогенной мимикрии (ВМ) была введена для описания уникальной способности высокоагрессивных опухолевых клеток формировать капиллярно-подобные структуры и богатую матрицами структурированную сеть в трехмерной культуре, которая имитирует эмбриональную васкулогенную сеть. Сообщалось о ВМ в нескольких агрессивных опухолях, включая рак яичников, молочной железы, печени, легких, саркому, глиобластому. Следует отметить, что ВМ в меланоцитарных опухолях наиболее распространена и является наиболее изученной. Хотя большое внимание уделялось факторам, которые стимулируют или подавляют образование сосудистых каналов опухолевыми клетками, молекулярные механизмы, лежащие в основе этого явления, остаются загадочными. Этот обзор будет посвящен молекулярным детерминантам и ключевым сигнальным путям, участвующим в опухолевой ВМ. Исследование лекарственных препаратов, нацеленных на молекулярные сигнальные пути в ВМ, является областью проблем и надежд. Исследования на ВМ увеличат наши знания о молекулярных событиях, дающих агрессивным опухолевым клеткам пластичность, что приводит к их способности имитировать сосудистую систему. На сегодняшний день существует мало функциональных данных, которые показывают, как каналы, связанные с опухолевыми клетками, способствуют общей выживаемости опухоли. Однако даже среди исследователей, которые поставили под сомнение концепцию ВМ как важнейшей системы кровообращения, в целом существует консенсус о том, что прогностическое значение PAS-положительных паттернов важно.</p></trans-abstract><kwd-group xml:lang="en"><kwd>vasculogenic mimicry</kwd><kwd>melanoma</kwd><kwd>prognostic</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>васкулогенная мимикрия</kwd><kwd>меланома</kwd><kwd>прогностическая роль</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Jain R.K., Carmeliet P. SnapShot: Tumor angiogenesis. Cell 2012;149(6):1408–1408.е1. DOI: 10.1016/j.cell.2012.05.025. PMID: 22682256.</mixed-citation><mixed-citation xml:lang="ru">Jain R.K., Carmeliet P. SnapShot: Tumor angiogenesis. Cell 2012;149(6):1408–1408.е1. DOI: 10.1016/j.cell.2012.05.025. PMID: 22682256.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Hilen F., Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26(3–4):489–502. DOI: 10.1007/s10555-007-9094-7. PMID: 17717633.</mixed-citation><mixed-citation xml:lang="ru">Hilen F., Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26(3–4):489–502. DOI: 10.1007/s10555-007-9094-7. PMID: 17717633.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Seftor R.E., Hess A.R., Seftor E.A. et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 2012;181(4):1115–25. DOI: 10.1016/j.ajpath.2012.07.013. PMID: 22944600.</mixed-citation><mixed-citation xml:lang="ru">Seftor R.E., Hess A.R., Seftor E.A. et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 2012;181(4):1115–25. DOI: 10.1016/j.ajpath.2012.07.013. PMID: 22944600.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Kirschmann D.A., Seftor E.A., Hardy K.M. et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012;18(10):2726–32. DOI: 10.1158/1078-0432.CCR-11-3237. PMID: 22474319.</mixed-citation><mixed-citation xml:lang="ru">Kirschmann D.A., Seftor E.A., Hardy K.M. et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012;18(10):2726–32. DOI: 10.1158/1078-0432.CCR-11-3237. PMID: 22474319.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Qiao L., Liang N., Zhang J. et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med 2015;19(2):315–26. DOI: 10.1111/jcmm.12496. PMID: 25598425.</mixed-citation><mixed-citation xml:lang="ru">Qiao L., Liang N., Zhang J. et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med 2015;19(2):315–26. DOI: 10.1111/jcmm.12496. PMID: 25598425.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Chung H.J., Mahalingam M. Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies. Expert Rev Anticancer Ther 2014;14(5):621–39. DOI: 10.1586/14737140.2014.883281. PMID: 24506089.</mixed-citation><mixed-citation xml:lang="ru">Chung H.J., Mahalingam M. Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies. Expert Rev Anticancer Ther 2014;14(5):621–39. DOI: 10.1586/14737140.2014.883281. PMID: 24506089.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Maniotis A.J., Folberg R., Hess A. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155(3):739–52. DOI: 10.1016/S0002-9440(10)65173-5. PMID: 10487832.</mixed-citation><mixed-citation xml:lang="ru">Maniotis A.J., Folberg R., Hess A. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155(3):739–52. DOI: 10.1016/S0002-9440(10)65173-5. PMID: 10487832.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156(2):361–81. DOI: 10.1016/S0002-9440(10)64739-6. PMID: 10666364.</mixed-citation><mixed-citation xml:lang="ru">Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156(2):361–81. DOI: 10.1016/S0002-9440(10)64739-6. PMID: 10666364.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Clarijs R., van Dijk M., Ruiter D.J., de Waal R.M. Functional and morphologic analysis of the fluid-conducting meshwork in xenografted cutaneous and primary uveal melanoma. Invest Ophthalmol Vis Sci 2015;46(9):3013–20. DOI: 10.1167/iovs.04-0876. PMID: 16123395.</mixed-citation><mixed-citation xml:lang="ru">Clarijs R., van Dijk M., Ruiter D.J., de Waal R.M. Functional and morphologic analysis of the fluid-conducting meshwork in xenografted cutaneous and primary uveal melanoma. Invest Ophthalmol Vis Sci 2015;46(9):3013–20. DOI: 10.1167/iovs.04-0876. PMID: 16123395.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Frenkel S., Barzel I., Levy J. et al. Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye (Lond) 2008;22(7):948–52. DOI: 10.1038/sj.eye.6702783. PMID: 17363922.</mixed-citation><mixed-citation xml:lang="ru">Frenkel S., Barzel I., Levy J. et al. Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye (Lond) 2008;22(7):948–52. DOI: 10.1038/sj.eye.6702783. PMID: 17363922.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. van Beurden A., Schmitz R.F., van Dijk C.M., Baeten C.I. Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. Melanoma Res 2012;22(6):424–9. DOI: 10.1097/CMR.0b013e328358b355. PMID: 23010821.</mixed-citation><mixed-citation xml:lang="ru">van Beurden A., Schmitz R.F., van Dijk C.M., Baeten C.I. Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. Melanoma Res 2012;22(6):424–9. DOI: 10.1097/CMR.0b013e328358b355. PMID: 23010821.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Chang Y.S., di Tomaso E., McDonald D.M. et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000;97(26):14608–13. DOI: 10.1073/pnas.97.26.14608. PMID: 11121063.</mixed-citation><mixed-citation xml:lang="ru">Chang Y.S., di Tomaso E., McDonald D.M. et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000;97(26):14608–13. DOI: 10.1073/pnas.97.26.14608. PMID: 11121063.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. di Tomaso E., Capen D., Haskell A. et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 2005;65(13):5740–9. DOI: 10.1158/0008-5472.CAN-04-4552. PMID: 15994949.</mixed-citation><mixed-citation xml:lang="ru">di Tomaso E., Capen D., Haskell A. et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 2005;65(13):5740–9. DOI: 10.1158/0008-5472.CAN-04-4552. PMID: 15994949.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Chen L., Zhang S., Li X. et al. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. Oncol Rep 2009;21(4):989–99. PMID: 19287998.</mixed-citation><mixed-citation xml:lang="ru">Chen L., Zhang S., Li X. et al. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. Oncol Rep 2009;21(4):989–99. PMID: 19287998.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Maniotis A.J., Chen X., Garcia C. et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab Invest 2012;82(8):1031–43. PMID: 12177242.</mixed-citation><mixed-citation xml:lang="ru">Maniotis A.J., Chen X., Garcia C. et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab Invest 2012;82(8):1031–43. PMID: 12177242.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Clarijs R., Otte-Holler I., Ruiter D.J., de Waal R.M. Presence of a fluidconducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 2002;43(4):912–8. PMID: 11923228.</mixed-citation><mixed-citation xml:lang="ru">Clarijs R., Otte-Holler I., Ruiter D.J., de Waal R.M. Presence of a fluidconducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 2002;43(4):912–8. PMID: 11923228.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Mueller A.J., Bartsch D.U., Folberg R. et al. Imaging the microvasculature of choroidal melanomas with confocal indocyanine green scanning laser ophthalmoscopy. Arch Ophthalmol 1998;116(1):31–9. PMID: 9445206.</mixed-citation><mixed-citation xml:lang="ru">Mueller A.J., Bartsch D.U., Folberg R. et al. Imaging the microvasculature of choroidal melanomas with confocal indocyanine green scanning laser ophthalmoscopy. Arch Ophthalmol 1998;116(1):31–9. PMID: 9445206.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Ruf W., Seftor E.A., Petrovan R.J. et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63(17):5381–9. PMID: 14500372.</mixed-citation><mixed-citation xml:lang="ru">Ruf W., Seftor E.A., Petrovan R.J. et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63(17):5381–9. PMID: 14500372.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Hess A.R., Seftor E.A., Gardner L.M. et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61(8):3250–5. PMID: 11309274.</mixed-citation><mixed-citation xml:lang="ru">Hess A.R., Seftor E.A., Gardner L.M. et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61(8):3250–5. PMID: 11309274.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Girouard S.D., Murphy G.F. Melanoma stem cells: not rare, but well done. Lab Invest 2011;91(5):647–64. DOI: 10.1038/labinvest.2011.50. PMID: 21445060.</mixed-citation><mixed-citation xml:lang="ru">Girouard S.D., Murphy G.F. Melanoma stem cells: not rare, but well done. Lab Invest 2011;91(5):647–64. DOI: 10.1038/labinvest.2011.50. PMID: 21445060.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Sajithlal G.B., McGuire T.F., Lu J. et al. Endothelial-like cells derived directly from human tumor xenografts. Int J Cancer 2010;127(10):2268–78. DOI: 10.1002/ijc.25251. PMID: 20162569.</mixed-citation><mixed-citation xml:lang="ru">Sajithlal G.B., McGuire T.F., Lu J. et al. Endothelial-like cells derived directly from human tumor xenografts. Int J Cancer 2010;127(10):2268–78. DOI: 10.1002/ijc.25251. PMID: 20162569.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Dunleavey J.M., Dudley A.C. Vascular mimicry: concepts and implications for anti-angiogenic therapy. Curr Angiogenes 2012;1(2):133–8. DOI: 10.2174/2211552811201020133. PMID: 24729954.</mixed-citation><mixed-citation xml:lang="ru">Dunleavey J.M., Dudley A.C. Vascular mimicry: concepts and implications for anti-angiogenic therapy. Curr Angiogenes 2012;1(2):133–8. DOI: 10.2174/2211552811201020133. PMID: 24729954.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Seftor E.A., Meltzer P.S., Schatteman G.C. et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002;44(1):17–27. PMID: 12398997.</mixed-citation><mixed-citation xml:lang="ru">Seftor E.A., Meltzer P.S., Schatteman G.C. et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002;44(1):17–27. PMID: 12398997.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. McAllister J.C., Zhan Q., Weishaupt C. et al. The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cutan Pathol 2010;37(Suppl 1):19–25. DOI: 10.1111/j.1600-0560.2010.01503.x. PMID: 20482672.</mixed-citation><mixed-citation xml:lang="ru">McAllister J.C., Zhan Q., Weishaupt C. et al. The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cutan Pathol 2010;37(Suppl 1):19–25. DOI: 10.1111/j.1600-0560.2010.01503.x. PMID: 20482672.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Khalkhali-Ellis Z., Kirschmann D.A., Seftor E.A. et al. Divergence(s) in Nodal signaling between aggressive melanoma and embryonic stem cells. Int J Cancer 2015;136(5):E242–51. DOI: 10.1002/ijc.29198. PMID: 25204799.</mixed-citation><mixed-citation xml:lang="ru">Khalkhali-Ellis Z., Kirschmann D.A., Seftor E.A. et al. Divergence(s) in Nodal signaling between aggressive melanoma and embryonic stem cells. Int J Cancer 2015;136(5):E242–51. DOI: 10.1002/ijc.29198. PMID: 25204799.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Frank N.Y., Schatton T., Kim S. et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71(4):1474–85. DOI: 10.1158/0008-5472.CAN-10-1660. PMID: 21212411.</mixed-citation><mixed-citation xml:lang="ru">Frank N.Y., Schatton T., Kim S. et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71(4):1474–85. DOI: 10.1158/0008-5472.CAN-10-1660. PMID: 21212411.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Murphy G.F., Wilson B.J., Girouard S.D. et al. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med 2014;39:33–49. DOI: 10.1016/j.mam.2013.10.003. PMID: 24145241.</mixed-citation><mixed-citation xml:lang="ru">Murphy G.F., Wilson B.J., Girouard S.D. et al. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med 2014;39:33–49. DOI: 10.1016/j.mam.2013.10.003. PMID: 24145241.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Lai C.Y., Schwartz B.E., Hsu M.Y. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res 2012;72(19):5111–8. DOI: 10.1158/0008-5472.CAN-12-0624. PMID: 22865455.</mixed-citation><mixed-citation xml:lang="ru">Lai C.Y., Schwartz B.E., Hsu M.Y. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res 2012;72(19):5111–8. DOI: 10.1158/0008-5472.CAN-12-0624. PMID: 22865455.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Valyi-Nagy K., Kormos B., Ali M. et al. Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures. Mol Vis 2012;18:588–92. PMID: 22419851.</mixed-citation><mixed-citation xml:lang="ru">Valyi-Nagy K., Kormos B., Ali M. et al. Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures. Mol Vis 2012;18:588–92. PMID: 22419851.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Demou Z.N., Hendrix M.J. Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma. J Cell Biochem 2008;105(2):562–73. DOI: 10.1002/ jcb.21855. PMID: 18655191.</mixed-citation><mixed-citation xml:lang="ru">Demou Z.N., Hendrix M.J. Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma. J Cell Biochem 2008;105(2):562–73. DOI: 10.1002/ jcb.21855. PMID: 18655191.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Bittner M., Meltzer P., Chen Y. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406(6795): 536–40. DOI: 10.1038/35020115. PMID: 10952317.</mixed-citation><mixed-citation xml:lang="ru">Bittner M., Meltzer P., Chen Y. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406(6795): 536–40. DOI: 10.1038/35020115. PMID: 10952317.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Hess A.R., Margaryan N.V., Seftor E.A., Hendrix M.J. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 2007;236(12):3283–96. DOI: 10.1002/dvdy.21190. PMID: 17557303.</mixed-citation><mixed-citation xml:lang="ru">Hess A.R., Margaryan N.V., Seftor E.A., Hendrix M.J. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 2007;236(12):3283–96. DOI: 10.1002/dvdy.21190. PMID: 17557303.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Margaryan N.V., Strizzi L., Abbott D.E. et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 2009;8(3):279–88. PMID: 19223760.</mixed-citation><mixed-citation xml:lang="ru">Margaryan N.V., Strizzi L., Abbott D.E. et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 2009;8(3):279–88. PMID: 19223760.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Hendrix M.J., Seftor E.A., Meltzer P.S. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001;98(14):8018–23. DOI: 10.1073/pnas.131209798. PMID: 11416160.</mixed-citation><mixed-citation xml:lang="ru">Hendrix M.J., Seftor E.A., Meltzer P.S. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001;98(14):8018–23. DOI: 10.1073/pnas.131209798. PMID: 11416160.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">35. Cong R., Sun Q., Yang L. et al. Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 2009;28:124. DOI: 10.1186/1756-996628-124. PMID: 19735546.</mixed-citation><mixed-citation xml:lang="ru">Cong R., Sun Q., Yang L. et al. Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 2009;28:124. DOI: 10.1186/1756-996628-124. PMID: 19735546.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">36. Liu R., Cao Z., Tu J. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma Res 2012;25(5):630–8. DOI: 10.1111/ j.1755-148X.2012.01036.x. PMID: 22781316.</mixed-citation><mixed-citation xml:lang="ru">Liu R., Cao Z., Tu J. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma Res 2012;25(5):630–8. DOI: 10.1111/ j.1755-148X.2012.01036.x. PMID: 22781316.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">37. Hess A.R., Seftor E.A., Gruman L.M. et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications. Cancer Biol Ther 2006;5(2):228–33. PMID: 16481735.</mixed-citation><mixed-citation xml:lang="ru">Hess A.R., Seftor E.A., Gruman L.M. et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications. Cancer Biol Ther 2006;5(2):228–33. PMID: 16481735.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">38. Hess A.R., Postovit L.M., Margaryan N.V. et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005;65(21):9851–60. DOI: 10.1158/0008-5472.CAN-05-2172. PMID: 16267008.</mixed-citation><mixed-citation xml:lang="ru">Hess A.R., Postovit L.M., Margaryan N.V. et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005;65(21):9851–60. DOI: 10.1158/0008-5472.CAN-05-2172. PMID: 16267008.</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">39. Hess A.R., Hendrix M.J. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 2006;5(5):478–80. DOI: 10.4161/cc.5.5.2518. PMID: 16552181.</mixed-citation><mixed-citation xml:lang="ru">Hess A.R., Hendrix M.J. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 2006;5(5):478–80. DOI: 10.4161/cc.5.5.2518. PMID: 16552181.</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">40. Lissitzky J.C., Parriaux D., Ristorcelli E. et al. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro. Cancer Res 2009;69(3):802–9. DOI: 10.1158/0008-5472.CAN-08-2391. PMID: 19176384.</mixed-citation><mixed-citation xml:lang="ru">Lissitzky J.C., Parriaux D., Ristorcelli E. et al. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro. Cancer Res 2009;69(3):802–9. DOI: 10.1158/0008-5472.CAN-08-2391. PMID: 19176384.</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">41. Chen L.X., He Y.J., Zhao S.Z. et al. Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/ PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 2011;11(2):229–35. PMID: 21084858.</mixed-citation><mixed-citation xml:lang="ru">Chen L.X., He Y.J., Zhao S.Z. et al. Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/ PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 2011;11(2):229–35. PMID: 21084858.</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">42. Seftor R.E., Seftor E.A., Koshikawa N. et al. Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/ metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2011;61(17):6322–7. PMID: 11522618.</mixed-citation><mixed-citation xml:lang="ru">Seftor R.E., Seftor E.A., Koshikawa N. et al. Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/ metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2011;61(17):6322–7. PMID: 11522618.</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">43. Seftor E.A., Meltzer P.S., Kirschmann D.A. et al. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 2006;10(1):174–96. PMID: 16563230.</mixed-citation><mixed-citation xml:lang="ru">Seftor E.A., Meltzer P.S., Kirschmann D.A. et al. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 2006;10(1):174–96. PMID: 16563230.</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">44. Hess A.R., Seftor E.A., Seftor R.E., Hendrix M.J. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003;63(16):4757–62. PMID: 12941789.</mixed-citation><mixed-citation xml:lang="ru">Hess A.R., Seftor E.A., Seftor R.E., Hendrix M.J. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003;63(16):4757–62. PMID: 12941789.</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">45. Zhang S., Li M., Gu Y. et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res 2008;27:60. DOI: 10.1186/1756-996627-60. PMID: 18983651.</mixed-citation><mixed-citation xml:lang="ru">Zhang S., Li M., Gu Y. et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res 2008;27:60. DOI: 10.1186/1756-996627-60. PMID: 18983651.</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">46. Zhang S., Zhang D., Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007;254(2):157–64. DOI: 10.1016/j.canlet.2006.12.036. PMID: 17306454.</mixed-citation><mixed-citation xml:lang="ru">Zhang S., Zhang D., Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007;254(2):157–64. DOI: 10.1016/j.canlet.2006.12.036. PMID: 17306454.</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">47. Seftor R.E., Seftor E.A., Kirschman D.A., Hendrix M.J. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 γ2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 2002;1(13): 1173–9. PMID: 12479698.</mixed-citation><mixed-citation xml:lang="ru">Seftor R.E., Seftor E.A., Kirschman D.A., Hendrix M.J. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 γ2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 2002;1(13): 1173–9. PMID: 12479698.</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">48. Zhao L., Marshall E.S., Kelland L.R., Baguley B.C. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs 2007;25(3):271–6. DOI: 10.1007/s10637-006-9029-0. PMID: 17203401.</mixed-citation><mixed-citation xml:lang="ru">Zhao L., Marshall E.S., Kelland L.R., Baguley B.C. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs 2007;25(3):271–6. DOI: 10.1007/s10637-006-9029-0. PMID: 17203401.</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">49. Hardy K.M., Kirschmann D.A., Seftor E.A. et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010;70(24):10340–50. DOI: 10.1158/0008-5472.CAN-10-0705. PMID: 21159651.</mixed-citation><mixed-citation xml:lang="ru">Hardy K.M., Kirschmann D.A., Seftor E.A. et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010;70(24):10340–50. DOI: 10.1158/0008-5472.CAN-10-0705. PMID: 21159651.</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">50. Strizzi L., Postovit L.M., Margaryan N.V. et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009;4(1):67–78. DOI: 10.1586/17469872.4.1.67. PMID: 19885369.</mixed-citation><mixed-citation xml:lang="ru">Strizzi L., Postovit L.M., Margaryan N.V. et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009;4(1):67–78. DOI: 10.1586/17469872.4.1.67. PMID: 19885369.</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">51. Sun B., Zhang D., Zhang S. et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007;249(2):188–97. DOI: 10.1016/j.canlet.2006.08.016. PMID: 16997457.</mixed-citation><mixed-citation xml:lang="ru">Sun B., Zhang D., Zhang S. et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007;249(2):188–97. DOI: 10.1016/j.canlet.2006.08.016. PMID: 16997457.</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">52. Zhao N., Sun B.C., Sun T. et al. Hypoxia-induced vasculogenic mimicry formation via VE-cadherin regulation by Bcl-2. Med Oncol 2012;29(5):3599–607. DOI: 10.1007/s12032-012-0245-5. PMID: 22562824.</mixed-citation><mixed-citation xml:lang="ru">Zhao N., Sun B.C., Sun T. et al. Hypoxia-induced vasculogenic mimicry formation via VE-cadherin regulation by Bcl-2. Med Oncol 2012;29(5):3599–607. DOI: 10.1007/s12032-012-0245-5. PMID: 22562824.</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">53. Comito G., Calvani M., Giannoni E. et al. HIF-1α stabilization by mitochondrial ROS promotes MET-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 2011;51(4):893–904. DOI: 10.1016/j.freeradbiomed.</mixed-citation><mixed-citation xml:lang="ru">Comito G., Calvani M., Giannoni E. et al. HIF-1α stabilization by mitochondrial ROS promotes MET-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 2011;51(4):893–904. DOI: 10.1016/j.freeradbiomed.</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">2011.05.042. PMID: 21703345. 54. Wu S., Singh R.K. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr Mol Med 2011;11(7):553–63. PMID: 21707515.</mixed-citation><mixed-citation xml:lang="ru">05.042. PMID: 21703345. 54. Wu S., Singh R.K. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr Mol Med 2011;11(7):553–63. PMID: 21707515.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">55. Benazzi C., Al-Dissi A., Chau C.H. et al. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. Scientific World Journal 2014;2014:919570. DOI: 10.1155/2014/919570. PMID: 24563633.</mixed-citation><mixed-citation xml:lang="ru">Benazzi C., Al-Dissi A., Chau C.H. et al. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. Scientific World Journal 2014;2014:919570. DOI: 10.1155/2014/919570. PMID: 24563633.</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">56. Schnegg C.I., Yang M.H., Ghosh S.K., Hsu M.Y. Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res 2015;75(8):1682–90. DOI: 10.1158/0008-5472.CAN-14-1855. PMID: 25769726.</mixed-citation><mixed-citation xml:lang="ru">Schnegg C.I., Yang M.H., Ghosh S.K., Hsu M.Y. Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res 2015;75(8):1682–90. DOI: 10.1158/0008-5472.CAN-14-1855. PMID: 25769726.</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">57. Vartanian A.A., Burova O.S., Stepanova E.V. et al. Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level. Melanoma Res 2007;17(6):370–9. DOI: 10.1097/CMR.0b013e3282f1d2ec. PMID: 17992120.</mixed-citation><mixed-citation xml:lang="ru">Vartanian A.A., Burova O.S., Stepanova E.V. et al. Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level. Melanoma Res 2007;17(6):370–9. DOI: 10.1097/CMR.0b013e3282f1d2ec. PMID: 17992120.</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">58. van der Schaft D.W., Seftor R.E., Seftor E.A. et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004;96(19):1473–7. DOI: 10.1093/jnci/ djh267. PMID: 15467037.</mixed-citation><mixed-citation xml:lang="ru">van der Schaft D.W., Seftor R.E., Seftor E.A. et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004;96(19):1473–7. DOI: 10.1093/jnci/ djh267. PMID: 15467037.</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><citation-alternatives><mixed-citation xml:lang="en">59. Spinella F., Caprara V., Di Castro V. et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med (Berl) 2013;91(3):395–405. DOI: 10.1007/s00109-012-0956-2. PMID: 22965194.</mixed-citation><mixed-citation xml:lang="ru">Spinella F., Caprara V., Di Castro V. et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med (Berl) 2013;91(3):395–405. DOI: 10.1007/s00109-012-0956-2. PMID: 22965194.</mixed-citation></citation-alternatives></ref><ref id="B60"><label>60.</label><citation-alternatives><mixed-citation xml:lang="en">60. Orgaz J.L., Ladhani O., Hoek K.S. et al. Loss of pigment epithelium derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 2008;28(47):4147–61. DOI: 10.1038/onc.2009.284. PMID: 19767774.</mixed-citation><mixed-citation xml:lang="ru">Orgaz J.L., Ladhani O., Hoek K.S. et al. Loss of pigment epithelium derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 2008;28(47):4147–61. DOI: 10.1038/onc.2009.284. PMID: 19767774.</mixed-citation></citation-alternatives></ref><ref id="B61"><label>61.</label><citation-alternatives><mixed-citation xml:lang="en">61. Rothhammer T., Bataille F., Spruss T. et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 2007;26(28):4158–70. DOI: 10.1038/sj.onc.1210182. PMID: 17173062.</mixed-citation><mixed-citation xml:lang="ru">Rothhammer T., Bataille F., Spruss T. et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 2007;26(28):4158–70. DOI: 10.1038/sj.onc.1210182. PMID: 17173062.</mixed-citation></citation-alternatives></ref><ref id="B62"><label>62.</label><citation-alternatives><mixed-citation xml:lang="en">62. Su F., Li B., Wang J. et al. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix ID2. Graefes Arch Clin Exp Ophthalmol 2009;247(3):411–9. DOI: 10.1007/s00417-008-1008-z. PMID: 19043732.</mixed-citation><mixed-citation xml:lang="ru">Su F., Li B., Wang J. et al. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix ID2. Graefes Arch Clin Exp Ophthalmol 2009;247(3):411–9. DOI: 10.1007/s00417-008-1008-z. PMID: 19043732.</mixed-citation></citation-alternatives></ref><ref id="B63"><label>63.</label><citation-alternatives><mixed-citation xml:lang="en">63. Liu Y.R., Sun B., Zhao X.L. et al. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res 2013;23(4):243–53. DOI: 10.1097/CMR.0b013e3283625498. PMID: 23695439.</mixed-citation><mixed-citation xml:lang="ru">Liu Y.R., Sun B., Zhao X.L. et al. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res 2013;23(4):243–53. DOI: 10.1097/CMR.0b013e3283625498. PMID: 23695439.</mixed-citation></citation-alternatives></ref><ref id="B64"><label>64.</label><citation-alternatives><mixed-citation xml:lang="en">64. Vartanian A.A., Burova O.S., Stepanova E.V., Baryshnikov A.Y. The involvement of apoptosis in melanoma vasculogenic mimicry. Melanoma Res 2007;17(1):1–8. DOI: 10.1097/ CMR.0b013e3280112b76. PMID: 17235236.</mixed-citation><mixed-citation xml:lang="ru">Vartanian A.A., Burova O.S., Stepanova E.V., Baryshnikov A.Y. The involvement of apoptosis in melanoma vasculogenic mimicry. Melanoma Res 2007;17(1):1–8. DOI: 10.1097/ CMR.0b013e3280112b76. PMID: 17235236.</mixed-citation></citation-alternatives></ref><ref id="B65"><label>65.</label><citation-alternatives><mixed-citation xml:lang="en">65. Mourad-Zeidan A.A., Melnikova V.O., Wang H. et al. Expression profiling of galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 2008;173(6):1839–52. DOI: 10.2353/ajpath.2008.080380. PMID: 18988806.</mixed-citation><mixed-citation xml:lang="ru">Mourad-Zeidan A.A., Melnikova V.O., Wang H. et al. Expression profiling of galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 2008;173(6):1839–52. DOI: 10.2353/ajpath.2008.080380. PMID: 18988806.</mixed-citation></citation-alternatives></ref><ref id="B66"><label>66.</label><citation-alternatives><mixed-citation xml:lang="en">66. Makitie T., Summanen P., Tarkkanen A., Kivela T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999;91(4):359–67. PMID: 10050870.</mixed-citation><mixed-citation xml:lang="ru">Makitie T., Summanen P., Tarkkanen A., Kivela T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999;91(4):359–67. PMID: 10050870.</mixed-citation></citation-alternatives></ref><ref id="B67"><label>67.</label><citation-alternatives><mixed-citation xml:lang="en">67. Folberg R., Rummelt V., Parys-Van Ginderdeuren R. et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100(9):1389–98. PMID: 8371929.</mixed-citation><mixed-citation xml:lang="ru">Folberg R., Rummelt V., Parys-Van Ginderdeuren R. et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100(9):1389–98. PMID: 8371929.</mixed-citation></citation-alternatives></ref><ref id="B68"><label>68.</label><citation-alternatives><mixed-citation xml:lang="en">68. Warso M.A., Maniotis A.J., Chen X. et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 2001;7(3):473–7. PMID: 11297236.</mixed-citation><mixed-citation xml:lang="ru">Warso M.A., Maniotis A.J., Chen X. et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 2001;7(3):473–7. PMID: 11297236.</mixed-citation></citation-alternatives></ref><ref id="B69"><label>69.</label><citation-alternatives><mixed-citation xml:lang="en">69. Cao Z., Bao M., Miele L. et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 2013;49(18):3914–23. DOI: 10.1016/j.ejca.2013.07.148. PMID: 23992642.</mixed-citation><mixed-citation xml:lang="ru">Cao Z., Bao M., Miele L. et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 2013;49(18):3914–23. DOI: 10.1016/j.ejca.2013.07.148. PMID: 23992642.</mixed-citation></citation-alternatives></ref><ref id="B70"><label>70.</label><citation-alternatives><mixed-citation xml:lang="en">70. Einspahr J.G., Thomas T.L., Saboda K. et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007;110(11):2519–27. DOI: 10.1002/cncr.23076. PMID: 17932890.</mixed-citation><mixed-citation xml:lang="ru">Einspahr J.G., Thomas T.L., Saboda K. et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007;110(11):2519–27. DOI: 10.1002/cncr.23076. PMID: 17932890.</mixed-citation></citation-alternatives></ref><ref id="B71"><label>71.</label><citation-alternatives><mixed-citation xml:lang="en">71. Modlin R.L., Gottlieb B., Taylor C., Rea T.H. Identification of cells lining pseudovascular spaces of benign pigmented nevi. Am J Dermatopathol 1984;6 Suppl:25–9. PMID: 6084957.</mixed-citation><mixed-citation xml:lang="ru">Modlin R.L., Gottlieb B., Taylor C., Rea T.H. Identification of cells lining pseudovascular spaces of benign pigmented nevi. Am J Dermatopathol 1984;6 Suppl:25–9. PMID: 6084957.</mixed-citation></citation-alternatives></ref><ref id="B72"><label>72.</label><citation-alternatives><mixed-citation xml:lang="en">72. Lee K.H., Han Y.W., Park C.J. Three cases of melanocytic nevi with pseudovascular spaces. Korean J Dermatol 2007;45(1):90–3.</mixed-citation><mixed-citation xml:lang="ru">Lee K.H., Han Y.W., Park C.J. Three cases of melanocytic nevi with pseudovascular spaces. Korean J Dermatol 2007;45(1):90–3.</mixed-citation></citation-alternatives></ref><ref id="B73"><label>73.</label><citation-alternatives><mixed-citation xml:lang="en">73. Demitsu T., Kakurai M., Yamada T. et al. The vascular space-like structure in melanocytic nevus is not an injection artifact: report of a case and an experimental study. J Dermatol 1998;25(3):143–9. PMID: 9575674.</mixed-citation><mixed-citation xml:lang="ru">Demitsu T., Kakurai M., Yamada T. et al. The vascular space-like structure in melanocytic nevus is not an injection artifact: report of a case and an experimental study. J Dermatol 1998;25(3):143–9. PMID: 9575674.</mixed-citation></citation-alternatives></ref><ref id="B74"><label>74.</label><citation-alternatives><mixed-citation xml:lang="en">74. Goldstein A.M., Tucker M.A. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 2013;22(4):528–32. DOI: 10.1158/1055-9965.EPI-12-1346. PMID: 23549396.</mixed-citation><mixed-citation xml:lang="ru">Goldstein A.M., Tucker M.A. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 2013;22(4):528–32. DOI: 10.1158/1055-9965.EPI-12-1346. PMID: 23549396.</mixed-citation></citation-alternatives></ref><ref id="B75"><label>75.</label><citation-alternatives><mixed-citation xml:lang="en">75. Coupland S.E., Lake S.L., Zeschnigk M., Damato B.E. Molecular pathology of uveal melanoma. Eye 2013;27(2):230–42. DOI: 10.1038/eye.2012.255. PMID: 23222563.</mixed-citation><mixed-citation xml:lang="ru">Coupland S.E., Lake S.L., Zeschnigk M., Damato B.E. Molecular pathology of uveal melanoma. Eye 2013;27(2):230–42. DOI: 10.1038/eye.2012.255. PMID: 23222563.</mixed-citation></citation-alternatives></ref><ref id="B76"><label>76.</label><citation-alternatives><mixed-citation xml:lang="en">76. Chang S.H., Worley L.A., Onken M.D., Harbour J.W. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 2008;18(3):191–200. DOI: 10.1097/ CMR.0b013e3283005270. PMID: 18477893.</mixed-citation><mixed-citation xml:lang="ru">Chang S.H., Worley L.A., Onken M.D., Harbour J.W. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 2008;18(3):191–200. DOI: 10.1097/ CMR.0b013e3283005270. PMID: 18477893.</mixed-citation></citation-alternatives></ref><ref id="B77"><label>77.</label><citation-alternatives><mixed-citation xml:lang="en">77. Gould Rothberg B.E., Bracken M.B., Rimm D.L. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101(7):452–74. DOI: 10.1093/jnci/djp038. PMID: 19318635.</mixed-citation><mixed-citation xml:lang="ru">Gould Rothberg B.E., Bracken M.B., Rimm D.L. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101(7):452–74. DOI: 10.1093/jnci/djp038. PMID: 19318635.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
